Mardi Dier - 04 Mar 2026 Form 4 Insider Report for MADRIGAL PHARMACEUTICALS, INC. (MDGL)

Role
EVP and CFO
Signature
/s/ Mardi Dier
Issuer symbol
MDGL
Transactions as of
04 Mar 2026
Net transactions value
-$853,993
Form type
4
Filing time
06 Mar 2026, 19:18:32 UTC
Previous filing
02 Mar 2026
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Dier Mardi EVP and CFO C/O MADRIGAL PHARMACEUTICALS, INC., 200 BARR HARBOR DRIVE, SUITE 200, WEST CONSHOHOCKEN /s/ Mardi Dier 06 Mar 2026 0001574591

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction MDGL Common Stock Award +5,215 +56% $0.000000* 14,472 04 Mar 2026 Direct F1
transaction MDGL Common Stock Sale $279,033 -646 -4.5% $431.94 13,826 06 Mar 2026 Direct F2
transaction MDGL Common Stock Sale $17,003 -40 -0.29% $425.08 13,786 06 Mar 2026 Direct F3
transaction MDGL Common Stock Sale $179,283 -420 -3% $426.86 13,366 06 Mar 2026 Direct F3, F4
transaction MDGL Common Stock Sale $34,228 -80 -0.6% $427.84 13,286 06 Mar 2026 Direct F3, F5
transaction MDGL Common Stock Sale $68,639 -160 -1.2% $429.00 13,126 06 Mar 2026 Direct F3, F6
transaction MDGL Common Stock Sale $17,183 -40 -0.3% $429.58 13,086 06 Mar 2026 Direct F3
transaction MDGL Common Stock Sale $51,708 -120 -0.92% $430.90 12,966 06 Mar 2026 Direct F3, F7
transaction MDGL Common Stock Sale $50,176 -116 -0.89% $432.56 12,850 06 Mar 2026 Direct F3, F8
transaction MDGL Common Stock Sale $69,472 -160 -1.2% $434.20 12,690 06 Mar 2026 Direct F3, F9
transaction MDGL Common Stock Sale $34,825 -80 -0.63% $435.32 12,610 06 Mar 2026 Direct F3, F10
transaction MDGL Common Stock Sale $34,935 -80 -0.63% $436.69 12,530 06 Mar 2026 Direct F3, F11
transaction MDGL Common Stock Sale $17,506 -40 -0.32% $437.65 12,490 06 Mar 2026 Direct F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction MDGL Stock Option (Right to Buy) Award +6,519 $0.000000* 6,519 04 Mar 2026 Common Stock 6,519 $434.80 Direct F12
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 Represents a grant of restricted stock units, which vest as to 25% of the shares on each of March 4, 2027, March 4, 2028, March 4, 2029 and March 4, 2030, provided the Reporting Person continues in service with the Issuer on each such date.
F2 This sale represents the number of shares sold by the Issuer on behalf of the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. This sale was automatic and not at the discretion of the Reporting Person.
F3 These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 2, 2025.
F4 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $426.46 to $427.08, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote and the footnotes below.
F5 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $427.50 to $428.19, inclusive.
F6 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $428.51 to $429.24, inclusive.
F7 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $430.66 to $431.04, inclusive.
F8 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $432.41 to $432.99, inclusive.
F9 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $433.82 to $434.58, inclusive.
F10 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $435.26 to $435.37, inclusive.
F11 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $436.46 to $436.92, inclusive.
F12 The option vests as to 25% of the shares on the first anniversary of the date of grant (March 4, 2027) and, thereafter, 6.25% of the shares shall vest on the last day of each successive three-month period, provided the Reporting Person continues in service with the Issuer on each such date.